decoding the language of the neuroimmune cross‑talk

  A new way to prevent and treat diseases through NRILs newly designed to reprogram the innate immune system

ABOUT US

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes – to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

Screen Shot 2020-05-05 at 5.38.32 PM.jpg

OUR SCIENCE

The discovery of Innate Lymphocyte Cells (ILCs) has triggered a paradigm shift in modern Immunology over the last decade.

These cytokine-producing immune cells, found in the fabric of tissues throughout the body, play critical roles in the regulation of inflammation, tissue repair, metabolic homeostasis, and defense against infection. Until recently however, the mechanisms by which ILCs perceive, integrate and respond to environmental signals were unknown.

Research by our Founder, Dr Henrique Veiga-Fernandes, helped to shine a light on these mechanisms, revealing a complex multidirectional system of cross-talk between neuronal and immune cells that enables precise coordination of the immune response.

Our pioneering technology platform leverages this crosstalk to manipulate ILC and neuronal regulation, targeting both upstream and downstream communications to open up previously unknown molecular pathways for therapeutic intervention. The wide-ranging influence of neuro-immune signaling in health and disease means that our approach has potential applications for a diverse array of disease indications.

In oncology for example, translating the multidirectional communication between cancer cells, immune cells, and the nervous system offers new avenues for the manipulation of neuro-immune checkpoint and co-stimulatory pathways, central to tumor progression and metastasis.

By decoding and harnessing the language of the neuroimmune cross-talk, the molecular cues used by the nervous system to orchestrate ILC activity, LiMM Therapeutics is developing first-in-class therapeutic products – NRILs: Neuronal Reprogrammers of Innate Lymphocytes – to preserve health and treat a range of disease indications.

PUBLICATIONS

Two papers from Dr Veiga-Fernandes’ lab, published in Nature in 2016 and 2017, were seminal in the field of decoding the language of the neuroimmune cross-talk. LiMM builds on this work to unlock therapeutic solutions for the benefit of patients.

From NATURE:

Screen Shot 2020-05-13 at 4.55.49 PM.jpg

JOIN LIMM

At LiMM, we’re on a mission to use world-class, multidisciplinary scientific approaches to develop first-in-class therapeutic products. Headquartered in Paris we’re also immersed in a culture of cutting-edge innovation, working at the heart of both France’s and Portugal’s biomedical research landscape.

The atmosphere of scientific excellence and beautiful location that LiMM enjoys allows us to thrive as a company, and as individuals, on our journey towards unlocking new therapeutic solutions for patients around the world.

Please check back for future openings.

INVESTORS

LiMM has attracted several firms to its investor base, including Seventure Partners, a leading venture capital firm in Europe with €750m net commitments under management, the 200M Co-investment Fund, managed by PME Investimentos, and Portugal Ventures, a venture capital firm that invests in innovative, scientific and technology-based Portuguese startups with significant competitive advantages.